09 Nov / 21
VANCOUVER, Wash., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter ended
28 Oct / 21
VANCOUVER, Wash., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced it will be participating virtually in the following investor
20 Oct / 21
Vancouver, Washington headquarters expands company’s ability to accelerate discovery and development of next generation biologic drugs VANCOUVER, Wash., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and
14 Oct / 21
VANCOUVER, Wash., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced it will report financial results for the third quarter 2021
07 Sep / 21
VANCOUVER, Wash., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter ended June 30,
21 Jul / 21
VANCOUVER, Wash., July 21, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (“Absci”), the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, today announced the pricing of its initial public offering of 12,500,000 shares of common stock at a public offering
Displaying 1 - 10 of 16